Aktuelle Ernährungsmedizin 2015; 40(03): 147-178
DOI: 10.1055/s-0034-1387650
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Adipositas im Erwachsenenalter

Obesity in Adulthood
S. C. Bischoff
Institut für Ernährungsmedizin, Universität Hohenheim
› Author Affiliations
Further Information

Publication History

Publication Date:
11 May 2015 (online)

Zusammenfassung

Adipositas im Erwachsenenalter betrifft ca. 20 % der Bevölkerung in Deutschland, wobei altersabhängige Unterschiede zu beachten sind. Im Erwachsenenalter steigt die Prävalenz von 15 auf über 30 % an, dennoch gibt es kaum Präventionskonzepte für diese Altersgruppe. Die Entwicklung der Epidemie Adipositas mit zahlreichen wichtigen Folgeerkrankungen in den letzten wenigen Jahrzehnten ist multifaktoriell. Sie umfasst genetische, epigenetische und mikrobielle Ursachen, aber auch Umweltfaktoren wie Überernährung, mangelnde Bewegung und psychosozialer Stress spielen eine zentrale Rolle. Während die Mechanismen der Adipositas gut untersucht sind, gibt es erhebliche Defizite in der bevölkerungsbezogenen Versorgungsforschung. Des Weiteren ist die Zuständigkeit für die Adipositasprävention und -therapie unzureichend geregelt, geeignete Infrastrukturen fehlen weitgehend und die Finanzierung bzw. finanzielle Unterstützung ist ungenügend. Aufgrund dieser und anderer Barrieren ist es bislang nicht gelungen, die Adipositasepidemie erfolgreich zu bekämpfen. Auf der anderen Seite ist Adipositas im Erwachsenenalter auf der Individualebene durchaus behandelbar, wenn die richtigen Maßnahmen ergriffen und geeignete Fachkräfte konsultiert werden. Während die Adipositas Grad I mittels verschiedener Ernährungs-, Bewegungs- und Verhaltensstrategien recht erfolgreich behandelt werden kann, gibt es für die Adipositas Grad II und III nur 2 wissenschaftlich belegte Therapieoptionen: validierte multimodale Gewichtsreduktionsprogramme über 6 – 12 Monate oder – im Fall unzureichenden Erfolgs – die Adipositaschirurgie. Dabei sind neben der Effektivität Sicherheitsaspekte ebenso zu beachten wie die Vermeidung von Muskelschwund, d. h. es geht um die möglichst selektive Reduktion von Fettgewebe und den weitgehenden Erhalt der Muskelmasse. Alle erfolgreichen Adipositastherapien benötigen eine in der Regel lebenslange Anschlussbehandlung, die die Gewichtserhaltung zum Ziel hat. Die Maßnahmen und Konzepte zur Gewichtserhaltung unterscheiden sich z. T. deutlich – sowohl, was die Ernährungs- als auch was die Bewegungstherapie angeht – von den Maßnahmen der Gewichtsreduktion.

Abstract

Obesity affects approximately 20 % of the adult population in Germany, with age-related differences being observed. In adults, the prevalence of obesity increases from 15 to more than 30 %, yet there are few prevention programs for this age group available. The evolution of the epidemic of obesity and most relevant associated diseases in the last few decades is multifactorial. It includes genetic, epigenetic and microbial causes, but also environmental factors such as diet, lack of exercise and psycho-social stress play a central role. While the mechanisms of obesity has been well studied, there are significant deficits in the population-based research on public health services. Furthermore, the responsibility for obesity prevention and treatment is inadequately regulated, appropriate infrastructure is largely absent and financing or financial assistance is insufficient. Because of these and other barriers, we have so far not been able to combat the obesity epidemic successfully. On the other hand, obesity in adulthood is at the individual level treatable, if the right measures are taken and appropriate professionals are consulted. While obesity grade I can be treated quite successfully by various nutritional, exercise and behavioral strategies, there are only two scientifically proven therapeutic options for obesity grade II and III, (1) validated multimodal weight loss programs for 6 – 12 months, or – in case of lack of success – (2) bariatric surgery. In addition to effectiveness, safety aspects and the prevention of muscle loss, i. e. the highly selective reduction of adipose tissue together with extensive preservation of muscle mass, has to be considered as well. All successful obesity therapies need usually life-long follow-up treatment. The measures and concepts for weight maintenance differ in some respect clearly from the measures of weight reduction – both regarding nutritional therapy and exercise coaching.

 
  • Literatur

  • 1 Willett WC. Balancing life-style and genomics research for disease prevention. Science 2002; 296: 695-698
  • 2 Berg A, Bischoff SC, Colombo-Benkmann M et al. S3-Leitlinie Adipositas 2014. Interdisziplinäre Leitlinie der Qualität S3 zur Prävention und Therapie der Adipositas. Im Internet: http://www.awmf.org/leitlinien/detail/ll/050-001.html (Stand: 23.03.2015)
  • 3 Knop C, Reinehr T. Adipositas im Kindes- und Jugendalter. Aktuel Ernahrungsmed 2015; 40: 109-122
  • 4 Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161
  • 5 Nazare JA, Smith J, Borel AL et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am J Cardiol 2015; 115: 307-315
  • 6 Swinburn BA, Sacks G, Hall KD et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814
  • 7 Max Rubner-Institut, Bundesforschungsinstitut für Ernährung und Lebensmittel. Nationale Verzehrsstudie II – Ergebnisbericht Teil 2 – Die bundesweite Befragung zur Ernährung von Jugendlichen und Erwachsenen. 2008. Im Internet: http://www.bmelv.de/SharedDocs/Downloads/Ernaehrung/NVS_ErgebnisberichtTeil2.pdf?__blob=publicationFile (Stand: 23.03.2015)
  • 8 Statistisches Bundesamt. Mikrozensus – Fragen zur Gesundheit – Körpermaße der Bevölkerung. 2011. Im Internet: https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Gesundheitszustand/Koerpermasse5239003099004.pdf?__blob=publicationFile (Stand: 23.03.2015)
  • 9 Kurth BM. Erste Ergebnisse aus der "Studie zur Gesundheit Erwachsener in Deutschland" (DEGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 980-990
  • 10 Han TS, Lee DM, Lean ME et al. EMAS Study Group. Associations of obesity with socioeconomic and lifestyle factors in middle-aged and elderly men: European Male Aging Study (EMAS). Eur J Endocrinol 2015; 172: 59-67
  • 11 Vernay M, Malon A, Oleko A et al. Association of socioeconomic status with overall overweight and central obesity in men and women: the French Nutrition and Health Survey 2006. BMC Public Health 2009; 9: 215
  • 12 Delavari M, Sønderlund AL, Swinburn B et al. Acculturation and obesity among migrant populations in high income countries – a systematic review. BMC Public Health 2013; 13: 458
  • 13 Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med 2007; 357: 370-379
  • 14 El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. Nat Rev Endocrinol 2013; 9: 402-413
  • 15 McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363: 2339-2350
  • 16 Levian C, Ruiz E, Yang X. The pathogenesis of obesity from a genomic and systems biology perspective. Yale J Biol Med 2014; 87: 113-126
  • 17 Misra A, Ganda OP. Migration and its impact on adiposity and type 2 diabetes. Nutrition 2007; 23: 696-708
  • 18 Bray GA, Paeratakul S, Popkin BM. Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 2004; 83: 549-555
  • 19 Lustig RH, Schmidt LA, Brindis CD. Public health: The toxic truth about sugar. Nature 2012; 482: 27-29
  • 20 de Ruyter JC, Olthof MR, Seidell JC et al. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367: 1397-1406
  • 21 Ebbeling CB, Feldman HA, Chomitz VR et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012; 367: 1407-1416
  • 22 Weber M, Grote V, Closa-Monasterolo R et al. European Childhood Obesity Trial Study Group. Lower protein content in infant formula reduces BMI and obesity risk at school age: follow-up of a randomized trial. Am J Clin Nutr 2014; 99: 1041-1051
  • 23 Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. Obesity (Silver Spring) 2008; 16: 643-653
  • 24 Rui L. Brain regulation of energy balance and body weight. Rev Endocr Metab Disord 2013; 14: 387-407
  • 25 Martínez JA, Milagro FI, Claycombe KJ et al. Epigenetics in adipose tissue, obesity, weight loss, and diabetes. Adv Nutr 2014; 5: 71-81
  • 26 Akabas S, Lederman SA, Moore BJ Hrsg. Textbook of obesity. Biological, Psychological and Cultural Influences. 1.. Aufl. Hoboken, NJ, USA: Wiley-Blackwell; 2012
  • 27 Ratzmann KP. Das metabolische Syndrom. Z Arztl Fortbild 1991; 85: 651-666
  • 28 Huang PL. A comprehensive definition for metabolic syndrome. Disease Models & Mechanisms 2009; 2: 231-237
  • 29 Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.. Diabetes Care 2005; 28: 2745-2749
  • 30 Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5: 295-309
  • 31 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107
  • 32 Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162
  • 33 Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887
  • 34 Dublin S, French B, Glazer NL et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166: 2322-2328
  • 35 Qin J, Li R, Raes J, et al. MetaHIT Consortium. Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65
  • 36 Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180
  • 37 Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249
  • 38 Spruss A, Kanuri G, Wagnerberger S et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-1104
  • 39 Volynets V, Küper MA, Strahl S et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012; 57: 1932-1941
  • 40 Bischoff SC, Barbara G, Buurman W et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189
  • 41 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725
  • 42 Lenz M, Richter T, Mühlhauser I. Morbidität und Mortalität bei Übergewicht und Adipositas im Erwachsenenalter: Eine systematische Übersicht. Dtsch Arztebl Int 2009; 106: 641-648
  • 43 Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-293
  • 44 Tausche AK, Jansen TL, Schröder HE et al. Gicht – aktuelle Aspekte in Diagnostik und Therapie. Dtsch Arztebl Int 2009; 106: 549-555
  • 45 Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
  • 46 Espeland MA, Glick HA, Bertoni A et al. Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes. Diabetes Care 2014; 37: 2548-2556
  • 47 DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol 2014; 10: 364-376
  • 48 Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591
  • 49 Kolotkin RL, Zunker C, Østbye T. Sexual functioning and obesity: a review. Obesity (Silver Spring) 2012; 20: 2325-2333
  • 50 Toups MS, Myers AK, Wisniewski SR et al. Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. Psychosom Med 2013; 75: 863-872
  • 51 Thibault R, Genton L, Pichard C. Body composition: why, when and for who?. Clin Nutr 2012; 31: 435-447
  • 52 Müller MJ, Lagerpusch M, Enderle J et al. Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev 2012; 13 (Suppl. 02) 6-13
  • 53 Bazzano LA, Hu T, Reynolds K et al. Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med 2014; 161: 309-318
  • 54 Rucker D, Padwal R, Li SK et al. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199
  • 55 Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-1294
  • 56 Kelley DE, Kuller LH, McKolanis TM et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40
  • 57 Filippatos TD, Derdemezis CS, Gazi IF et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65
  • 58 Miura J, Arai K, Tsukahara S et al. The long-term effectiveness of combined therapy by behavior modification and very low calorie diet: 2 years follow-up. Int J Obes 1989; 13 (Suppl. 02) 73-77
  • 59 Furlow EA, Anderson JW. A systematic review of targeted outcomes associated with a medically supervised commercial weight-loss program. J Am Diet Assoc 2009; 109: 1417-1421
  • 60 Hemmingsson E, Johansson K, Eriksson J et al. Weight loss and dropout during a commercial weight-loss program including a very-low-calorie diet, a low-calorie diet, or restricted normal food: observational cohort study. Am J Clin Nutr 2012; 96: 953-961
  • 61 Bischoff SC, Damms-Machado A, Betz C et al. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life – a prospective study. Int J Obes (Lond) 2012; 36: 614-624
  • 62 Astrup A, Rössner S. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes Rev 2000; 1: 17-19
  • 63 Purcell K, Sumithran P, Prendergast LA et al. The effect of rate of weight loss on long-term weight management: a randomised controlled trial. Lancet Diabetes Endocrinol 2014; 2: 954-962
  • 64 Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154
  • 65 Sjöström L, Narbro K, Sjöström CD et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752
  • 66 Puzziferri N, Roshek 3rd TB, Mayo HG et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312: 934-942
  • 67 Flum DR, Belle SH, King WC et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445-454
  • 68 Courcoulas AP, Christian NJ, Belle SH et al. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 2013; 310: 2416-2425
  • 69 Ross Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev 2012; 13: 509-517
  • 70 Catenacci VA, Ogden LG, Stuht J et al. Physical activity patterns in the National Weight Control Registry. Obesity (Silver Spring) 2008; 16: 153-161
  • 71 Clifton PM, Condo D, Keogh JB. Long-term weight maintenance after advice to consume low carbohydrate, higher protein diets - -a systematic review and meta analysis. Nutr Metab Cardiovasc Dis 2014; 24: 224-235
  • 72 Estruch R, Ros E, Salas-Salvadó J et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290
  • 73 Esposito K, Maiorino MI, Petrizzo M et al. The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial. Diabetes Care 2014; 37: 1824-1830
  • 74 Peirson L, Douketis J, Ciliska D et al. Prevention of overweight and obesity in adult populations: a systematic review. CMAJ Open 2014; 2: E268-272
  • 75 Astrup A, Brand-Miller J. Obesity: Have new guidelines overlooked the role of diet composition?. Nat Rev Endocrinol 2014; 10: 132-133
  • 76 Levine JA, Lanningham-Foster LM, McCrady SK et al. Interindividual variation in posture allocation: possible role in human obesity. Science 2005; 307: 584-586
  • 77 Dietz WH, Baur LA, Hall K et al. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet 2015; pii: S0140-6736(14)61748-61747
  • 78 Roberto CA, Swinburn B, Hawkes C et al. Patchy progress on obesity prevention: emerging examples, entrenched barriers, and new thinking. Lancet 2015; pii: S0140-6736(14)61744-X